Bristol-Myers Squibb Company
I · AI Analysis
The brief
Bristol-Myers Squibb discovers, develops, manufactures, and sells prescription medicines worldwide, focusing on cancer treatments (Opdivo, Yervoy, Breyanzi), immune system drugs (Orencia, Zeposia), blood disorder treatments (Reblozyl, Revlimid), and cardiovascular medicines (Eliquis) [Yahoo Finance]. The company sells through wholesalers, specialty pharmacies, hospitals, and government agencies across global markets [Yahoo Finance].
Bristol-Myers Squibb is a large pharmaceutical company that develops and sells drugs for cancer, immune diseases, heart conditions, and neurological disorders [Yahoo Finance]. The company generates $48.2B in annual revenue, maintains a $119B market cap, and is financially healthy with strong cash flow [Yahoo Finance]. Recent news highlights aggressive AI partnerships with Anthropic and Tempus AI to accelerate drug discovery, plus a major $1B manufacturing expansion in Houston [Yahoo Finance].
Bristol-Myers Squibb is financially healthy with strong profitability and solid cash generation, though revenue is flat year-over-year [Yahoo Finance].
Sentinellis health
7.4/10
Moderate concerns
Market capitalisation
$119.1B
Revenue (TTM)
$48.2B
Explainers
How we read these numbers
Plain-English guides · no account needed
ROIC vs WACC Explained: How to Tell If a Company Actually Creates Value
What ROIC and WACC are, how to compute both, and why the spread between them is the single most important number in fundamental investing.
ReadPiotroski F-Score Explained: A 9-Point Financial Health Check (with a Live Apple Example)
What the Piotroski F-Score is, how to calculate all 9 criteria, and how to read the result. Plain English, with a real Apple walkthrough.
ReadAltman Z-Score Explained: Predicting Bankruptcy in 5 Minutes (with Real Examples)
What the Altman Z-Score is, the exact formula, how to read the result, and which version to use for manufacturers vs tech vs private companies.
ReadII · Recent news
What moved
6 stories · ranked by relevance
- Macro2026-05-20
Bristol Myers Squibb Announces Strategic Agreement with Anthropic to Position Claude Enterprise as the Shared Intelligence Platform Across Its Global Operations
Yahoo Finance
- Macro2026-05-19
How The Bristol Myers Squibb (BMY) Story Is Shifting Around Pipeline Hopes And Patent Risks
Simply Wall St
- Macro2026-05-20
Bristol Myers to deploy Anthropic's Claude AI model to speed up drug discovery
Yahoo Finance
- Macro2026-05-18
Tempus AI, Bristol Myers Squibb Expand AI-Driven Clinical Trial Efforts
Benzinga
- Macro2026-05-19
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It
Zacks
- Macro2026-05-18
Tempus AI And BMS Deepen AI Drug Development Ties As Losses Persist
Simply Wall St
Premium · Free with any account
Revenue is flat year-over-year at -0.2%, signaling potential challenges in maintaining growth momentum as key drug patents approach expiration [Yahoo Finance].
Risks
4
Opportunities
6
Red flags
1
Leadership
10
10 more findings in the full report — free with any account.
Unlock the full Bristol-Myers Squibb Company analysis
Create a free account to access the complete AI-generated report with inline citations.
- 4 risks, 6 opportunities and 1 red flag — each with its source
- 100+ financial metrics with charts and benchmarks
- Full news summaries with source links
- Executive team and compensation details
- PDF export for offline use
III · Related
You might also read
Same sector · Healthcare — or comparable health
Want this for your watchlist?